Tag: ASX: CSL
Australia’s CSL outlines USD 1.5B plan to boost US plasma therapy manufacturing capacity
Australian biotech firm CSL has announced plans to invest approximately USD 1.5 billion in the United States over the next five years, with the company stating the move is aimed at strengthening domestic manufacturing capacity for plasma-derived therapies.
Featured Article
Reducing downtime through real-time shop floor insights with Minitab’s Prolink
Unplanned downtime remains one of the most costly – and often misunderstood – challenges on the manufacturing floor.
